Available from: /current-events/obesity-drugs 7 Goldman Sachs, 2023
So far, more than 400 complaints have been filed against Ro via the BBB
Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases
"Compounding medicines on a commercial-like scale has the potential to adversely affect many patients, as they are not subject to rigorous testing for safety and quality." The TGA also warned practitioners prescribing and dispensing compounded medication "should consider their individual legal and professional responsibility in prescribing and dispensing an 'unapproved' product, including compounded semaglutide-like products"
There was no significant difference in plasma total cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, leptin, adiponectin, resistin or interleukin-6 in Gipr Syn/ mice compared to Gipr fl/fl mice, although plasma tumour necrosis factor (TNF) and monocyte chemoattractant protein-1 (MCP-1) were lower in Gipr Syn/ mice than in Gipr fl/fl mice (Extended Data Fig